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Background: This study sought to examine the effect of targeted physical therapy with and without cranial nerve
non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibited a dysfunctional
gait. We hypothesized that subjects who received electrical stimulation would have greater improvement than
those who had a control device after a 14-week intervention. Gait disturbance is a common problem for people
with multiple sclerosis (MS). Current management may include exercise, pharmacology, functional electrical
stimulation, compensatory strategies, use of assistive devices, and implanted electrical devices. We have developed
an effective rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the
tongue to enhance the plasticity of the brain.
Methods: The study is a within-subject blinded randomized control design. Twenty chronic MS subjects with an
identified gait disturbance were assigned to either an active or control group. Both groups completed a 14-week
intervention program using a standardized combination of exercise and a device that provided electrical stimulation
to the tongue. Those in the active group received electrical stimulation on the tongue that they could perceive.
Those in the control group used a device that did not provide a physiologically significant stimulus and was not
perceivable. Subjects were assessed with the Dynamic Gait Index (DGI).
Results: The DGI scores improved for both groups. There were significant between-group differences, with the
active group showing statistically greater improvement than the control group mean.
Conclusion: People with MS demonstrated improved gait with CN-NINM training in a pilot randomized controlled
trial. This study suggests that tongue-based neurostimulation may amplify the benefits of exercise for improving
gait in people with chronic MS.
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Individuals with moderate multiple sclerosis (MS) present
with an array of symptoms, with walking impairment being
among the most common. Gait speed, cadence, stride
length and time spent on double-limb support are fre-
quently affected, and correlate with reduced independence
and productivity, impacting overall quality of life [1]. It is a
major factor in estimates of disease progression [2-4], and* Correspondence: kzskinner@wisc.edu
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reproduction in any medium, provided the orapproximately 40% of MS patients will need some form of
walking assistance within 15 years of disease onset [5].
Consequently, interventions targeting gait disturbance in
patients with MS are in demand. Currently these include
rehabilitation therapy and pharmacological management.
While therapeutic exercise has long been believed to
increase symptoms, more recent evidence has demon-
strated that exercise and increased physical activity are
beneficial for people with MS, and are becoming more
commonly included as part of treatment interventions
[6-10]. The optimal type or mode of exercise, intensity,
frequency, duration and maintenance of exercise trainingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tion in MS has, however, yet to be established through
randomized trials [3].
Rehabilitation therapy includes occupational, physical
and speech therapies as part of the comprehensive man-
agement of symptoms [11,12]. Compensatory strategies
such as energy conservation, use of adaptive equipment,
and environmental adaptations are often utilized in these
interventions [13-20]. Medical devices and physical mo-
dalities may also be used in multidisciplinary interven-
tions [21]. A recent Cochrane review of multidisciplinary
rehabilitation for adults with MS did not find strong evi-
dence of interventions that resulted long-term improve-
ments [12].
Pharmacological management may slow disease pro-
gress or reduce motor symptoms. For example, Ampyra
(Acorda Therapeutics) was approved after it was shown
to be effective in improving walking speed by 20% when
compared to a placebo group that improved 8% [2]. This
outcome, however, was observed in only 35% of those
tested, and many participants reported significant side
effects. Additionally, there is little evidence that these
drugs will prevent the mobility disability of persons with
2nd stage MS (Kurtzke Expanded Disability Status Scale
(EDSS) score of 4.0 or greater) [1,3,22,23].
The medical devices and physical modalities utilized in
treatment for people with MS vary. Functional electrical
stimulation, as delivered through electrodes attached to
the skin, has been shown to be effective in improving gait,
as long as the electrodes are attached and the stimulation
unit is on [24-29]. Other contemporary forms of neurosti-
mulation (aimed at induced neuromodulation) are inva-
sive, expensive and have the potential for adverse effects.
For example, deep brain stimulation and vagus nerve
stimulation, which use implanted pacemaker-like electrical
devices, are indicated for decreasing tremors in MS, but
carry surgical risks [30-33]. These therapies have not been
widely attempted in MS rehabilitation. Neurostimulation
that directly stimulates the peripheral or central nervous
systems to improve motor impairments is still being inves-
tigated. Non-invasive neurostimulation that has been tried
in people with MS are typically large clinic-based devices
that employ powerful electromagnetic stimulation of
the brain’s cortex (transcranial magnetic stimulation)
[34,35], or electrodes that pass electric current through
the skull (transcranial direct current brain stimulation)
[36,37]. Intermittent theta burst stimulation of the motor
cortex has been demonstrated to reduce spasticity in
people with MS [38], and when combined with exercise
therapy, to decrease fatigue [35]. Success with these inter-
ventions has, however, been limited. Consequently, there
continues to be a need for alternative approaches that
have the potential to help improve mobility in people
with MS.Previous studies have shown that the tongue can be used
as an effective interface for sending electrical signals to
the central nervous system [39-45], for example sensory
substitution in balance-impaired or blind individuals
[43,46-49,50]. Individuals with primary vestibular disor-
ders who trained using electrical stimulation through
the tongue coupled to head-position information dem-
onstrated balance improvements that were sustained
for weeks beyond the final stimulation session [46,51].
Using a different methodology that delivers tongue
stimulation which, like the present study, is devoid of in-
formation linked to head position or any other exogen-
ous variable, our recent functional MRI results indicated
that the improvements that occurred with the neuromo-
dulation training (using electrical stimulation on the
tongue) are likely related to modulation of neural activ-
ity within structures of the brain that control balance
and movement [44,45,52].
Objective
This study sought to examine the effect of targeted
physical therapy, with and without cranial nerve non-
invasive neuromodulation (CN-NINM), on the walking
ability of people with MS who exhibited a dysfunctional
gait. We hypothesized that subjects who received elec-
trical stimulation on the tongue would have greater im-




The study was a randomized, double blind controlled trial.
Twenty subjects (males and females) with identified gait
deficits due to the effects of MS were distributed into 2
treatment groups: 10 used an “Active” CN-NINM device,
or Portable Neuromodulation Stimulator (PoNS™), and 10
used a “Control” (very low stimulation) device. The study
consisted of two phases: 2 weeks of twice-daily gait train-
ing in the laboratory while using the PoNS, followed by
12 weeks of the same daily routine at home. All subjects
performed the same gait training over the period of the
study. All subjects were tested at the beginning and end of
the first phase, and every 4 weeks during the second
phase. The structure of the study is depicted in Figure 1.
Subjects
Twenty-six subjects with stable symptoms from MS were
recruited by physician and subject referrals. Because gait
impairment can be manifested in persons with any type of
MS, we thought it was important to include people with
any type of MS who were affected by a walking impair-
ment. Inclusion criteria were: relapsing remitting (RRMS),
primary progressive (PPMS), or secondary progressive
(SPMS) without relapse within 6 months of enrollment in
Figure 1 Detailed flow chart of the study intervention.




Mean SD Mean SD p
Age 55.40 8.73 51.90 9.31 0.40
Years with MS 24.10 11.03 13.10 6.72 0.01*
EDSS 5.25 0.98 4.60 1.05 0.17
DGI 8.90 2.85 11.95 4.04 0.07
*Indicates significant difference.
EDSS, Expanded Disability Status Scale, DGI = Dynamic Gait Index.
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cation within 3 months of enrollment; and ability to walk
20 minutes on a treadmill (with handrail support as
needed) without rest. The EDSS is a rating system used
for classifying the condition of people with MS, and em-
phasizes walking ability. Scores in the range of 3.5 to 6.0
on the EDSS represent people who are ambulatory and
have a few functional systems affected to those more sig-
nificantly affected, requiring intermittent or constant uni-
lateral assistance (e.g., a cane, crutch, or brace) to walk
100 meters with or without resting.
Exclusion criteria were: major co-morbidities, espe-
cially other neurological disorders, uncontrolled pain,
hypertension, diabetes, or oral health problems. A sum-
mary of the subjects’ general characteristics is presented
in Table 1. Three subjects (2 Control, 1 Active) were
on neurostimulating medication (e.g. fampridine) that
might alter motor function. Five subjects were on anti-
inflammatory medications, six on antispasmodics, and
six had non-narcotic prescriptions to manage chronic
pain. Four candidates were not enrolled because they
did not meet the inclusion criteria, and two did not par-
ticipate because they could not meet the time commit-
ments of the study.The University of Wisconsin-Madison Health Sciences
Institutional Review Board approved this study and all
subjects gave written consent before participation.
Randomization and blinding
Subjects were randomly assigned to either the control or
active group by the primary investigator (PI) as they en-
rolled in the study. Ten subjects were assigned to each
group, with no regard given to age, gender, individual
EDSS score, disease state, functional status, or chronicity
of MS. The PI provided each subject with the proper
Figure 2 Portable Neuromodulation Stimulator (PoNS™) device,
top and bottom view.
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use. The subjects in the active group used a device that
provided electrical stimulation on the tongue that they
could perceive. Those in the control group used a device
that provided a stimulus that was not perceivable. Subjects
were instructed that this was controlled study investigat-
ing the effects of stimulus level so they may or may not
feel the stimulation. To avoid deception, all subjects in
both groups were assured that they were in fact receiving
stimulation, whether or not they could feel the stimu-
lus. The subjects and the therapists providing the inter-
vention and testing were not informed which group a
subject was assigned. In order to maintaining blinding,
both subjects and therapists were instructed to not dis-
cuss any details of the stimulus sensation with each other.
Additionally, all subjects were instructed to not adjust the
stimulus intensity in the presence of the therapist. All
questions about device use or the stimulation were to be
addressed only to the PI. A summary of subject distribu-
tion in the two cohorts is presented in Table 2.
Experimental procedures
Intervention
The goal of the training was to develop a more normal
gait pattern. The twice-daily intervention was identical
for each subject, and progressed in two phases: a 2-week
twice daily in-lab phase, followed by a 12-week at-home
phase where subjects performed the same training as
instructed in the laboratory. The structure and progres-
sion of both the in-lab and at-home interventions, as
well as the assessments, are shown in Figure 1. Subjects
were telephoned weekly during the at-home phase to en-
sure compliance with the protocol. In order to maximize
any potential benefit from participation, the degree of
challenge in each subject’s training program was in-
creased according to the progress they made at each
4-week follow-up visit for testing and retraining.
Device
Electrical stimulation to the tongue was delivered via the
Portable Neuromodulation Stimulator (PoNS™) device
shown in Figure 2. The PoNS™ device was held in place
lightly by the lips and teeth around a rectangular tabTable 2 Multiple sclerosis subgroups
Active (10) Control (10)
Relapsing Remitting 5 8
Male/Female 1/4 2/6
Secondary Progressive 5 1
Male/Female 3/2 0/1
Primary Progressive 0 1
Male/Female 0/0 0/1that goes into the mouth and rests on the anterior, su-
perior part of the tongue. The tab has 144 exposed gold-
plated circular electrodes (1.5 mm diam., on 2.3-mm
centers) on a 3 cm × 3 cm square matrix on a rigid
printed circuit board that is coated with a biocompatible
epoxy (Epotech 302-3 M, Epoxy Technology, Billerica,
MA). The 12x12 array is divided into nine 4x4 sectors.
Only one electrode in each sector is pulsed at any given
time; the remaining electrodes serve as the return current
path. The stimulation on each electrode is a triplet of
50 μs-wide positive pulses delivered at 200 pulses/s every
20 ms. Capacitive coupling ensures zero net direct current
to minimize the possibility of tissue irritation. Electrode
and waveform parameters were derived from earlier re-
search aimed at developing electrotactile stimulation that
is maximally comfortable and controllable [53-56], and
implemented using circuitry similar to that in the earlier
Tongue Display Unit [51].
Device function is user-controlled by buttons for ‘On’
and ‘Off,’ and subjects could adjust the stimulus level
(pulse amplitude) from 0 to 17 volts by manipulating a
knob on the device (see Figure 2). The “Control” version
of the device was physically identical to the Active de-
vice, but delivered a stimulus at approximately 1/1,000
the minimum perceivable level. Here, adjustment of the
intensity knob did not change this level.
To avoid bias or deception, subjects in both groups were
provided with identical instructions to adjust the intensity
level by turning the knob. They were told that they may
or may not feel the stimulation. If they could feel the
stimulus, they were to adjust the intensity until it was
strong but not uncomfortable. We allowed individual ad-
justment rather than setting a fixed amplitude across all
subjects, because of known inter-subject differences in
tongue sensitivity, with the rationale that it is more im-
portant to hold invariant the result of the stimulation
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search, we have observed that with experience, subjects
set the intensity level at between 50 and 80% of the max-
imum dynamic range of sensation [43-48,50-52]. If sub-
jects could not feel it, they were reassured that they were
still receiving stimulation but it was below their individual
threshold of perception.
CN-NINM training
Instruction and implementation of the 14-week interven-
tion was identical for both groups. Subjects trained in the
lab for 5 consecutive days (Monday through Friday) for 2
consecutive weeks working one-on-one with a therapist
researcher for all in-laboratory training sessions. Subjects
then continued the same training independently at home
for the next 12 weeks. Subjects returned to the lab every
4 weeks for assessment, training review, and exercise pro-
gram progression. Compliance was monitored daily in the
lab, and weekly via self-reports by phone when the sub-
jects trained at home.
The in-lab training consisted of two appointments per
day. Within each appointment, subjects performed
movement isolation exercises without the device, 20
minutes of gait training with the device, 20 minutes of
balance training with the device, and 20 minutes of re-
laxation training with the device. The training was tar-
geted to the specific ability of each individual, and they
were provided with rest periods as needed. Subjects who
were unable to complete the training components in the
lab due to fatigue were allowed to delay that component
until later in the day after they had had an opportunity
to rest. Subjects were also expected to incorporate an
additional relaxation session with the device at home
each evening one hour before bed.
Subjects were instructed in movement isolation exer-
cises (without device) at the beginning of each training
session. These were geared to the ability of that individual.
These exercises were designed to change abnormal move-
ment patterns and re-train movements for improved
neuromuscular control and mobility. Sample exercises
were chin circles, shoulder circles, and hip circles. The
emphasis was placed on quality of movements, not speed,
and mirrors were used to provide visual feedback as
needed. As the individual demonstrated competency with
an exercise, new exercises were introduced.
During gait training subjects walked on a treadmill at
progressive speeds and challenges designed to re-establish
appropriate dynamic balance and gait patterns. Particular
attention was given to symmetry of the gait pattern, in-
cluding dynamic weight transfer, stride length, kinematics
of the hip, knee, and ankle flexions/extensions, and bilat-
eral symmetry of the stance and swing phases. In-lab gait
training was performed on the treadmill for the first week,
and both over ground and on the treadmill during thesecond week. Subjects were required to use a treadmill for
at least 50% of the at-home training phase to control and
monitor their training progress.
Gait training sessions were 20 minutes in overall dur-
ation. The first 5 minutes were performed at a comfort-
able pace. In the next two 5-minute periods the
challenge was increased by changing a gait variable. The
last 5-minute period was performed at a comfortable in-
tensity but greater than that for the first 5-minute
period. The variables were:
 Speed: from very slow to fast walking, focusing on
maintaining gait kinematics without deterioration of
performance;
 Grade: an incline increases effort and affects the
relative involvement of the ankle, knee and hip joints;
 Support: use of handrails provides greater stability,
but prevents arm swing and full weight transfer
during the gait cycle. Challenge was created by
decreasing hand contact time and force on the rails,
with the goal of achieving arm swing commensurate
with normal gait.
The therapist worked with the subject to determine
an appropriate starting point relative to the subject’s
baseline. The objective of each session of gait train-
ing was to start at a higher level than the previous
session. The therapist used verbal and tactile cues as
needed to correct posture and abnormal movement
patterns during gait.
Balance training (with device) was performed by hav-
ing the subjects stand on the floor or on foam with eyes
closed, depending on their ability. As in gait training,
balance training was targeted to each subject, advancing
their challenge as they improved. To increase the bal-
ance challenge, subjects could change their stance width,
foot position, or stand barefoot. Subjects stood close to a
table for support if needed, and were guarded against
falls by the therapist providing stand-by assist if needed.
Relaxation training (with device) was performed in an
unsupported sitting position while wearing headphones
and listening to theta-wave based sound tracks. Subjects
were instructed in diaphragmatic breathing and main-
taining relaxed attention.
Assessments
Subjects completed the Dynamic Gait Index (DGI), a
clinician-scored index of 8 gait tasks: normal walking,
changing speed while walking, head turns and up/
down tilts while walking, turning and stopping, walk-
ing around and stepping over objects, and traversing
stairs [13,57-59]. This test was performed at baseline, after
the 2-week in-lab intervention, and after 4, 8 and 12 weeks
of at-home training (a total of 14 weeks intervention) for
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to provide daily (in-lab) and weekly (at-home) written
documentation of their at-home training program in order
to monitor compliance with the protocol.
The EDSS is a clinical tool for assessing and com-
paring patients’ global neurological disability and was
not used to assess any changes in gait. It was used
only for entrance criteria for the study. The final score
reflects the status of many functional systems and may
not be impacted by changes in gait. It has been shown
to lack responsiveness to change and is therefore not
recommended for research as an assessment tool for
measuring change.
Data analysis
Statistical analyses were completed with Systat version 8.0
(SPSS, Inc.). The demographic data presented in Table 1
were examined by descriptive statistics and the differences
between active and control groups were compared using
unpaired, two-tailed t-tests. DGI data summarized in
Table 3 were also examined with descriptive statistics.
DGI differences from baseline (week 0) were calculated
for the 2, 6, 10, and 14-week test points and subjected to
analysis of variance, separately for active and control
groups; multiple comparisons for these analyses were per-
formed with a Tukey HSD test and are shown in Table 3.
Finally, the DGI differences from baseline were compared
for the active and control groups using unpaired, two-
tailed t-tests, separately for the 2, 6, 10, and 14 week data
points. Although the DGI scale is technically categorical,
it has been shown to have good psychometric properties
[13,58-60]. As a precaution we repeated the latter analyses
using the non-parametric Wilcoxon Rank Sum Test.
Results
Twenty people with MS participated in this study. The
subjects were randomized into active and control groups
as they enrolled. The groups were similar across age and
EDSS scores (see Table 1). There was a difference be-
tween the groups for mean number of years with a diag-
nosis of MS (p = 0.01) and for baseline DGI, althoughTable 3 DGI Mean Scores
Active Control
Week N Mean (SD) Diffa pa N Mean (SD) Diffa pa
0 10 8.90 (2.85) 10 11.95 (4.04)
2 10 13.30 (3.92) 4.40c 0.056 10 14.95 (4.29) 3.00 0.610
6 10 15.05 (3.53) 6.15c 0.003b 8 15.63 (4.73) 3.68 0.471
10 10 16.60 (3.95) 7.70c <0.001b 10 16.75 (5.20) 4.80c 0.166
14 10 16.85 (3.40) 7.95c <0.001b 10 15.40 (5.03) 3.45 0.745
aDifference from baseline (week 0).
bStatistically significant difference (p < .05).
cClinically significant difference (> = 4).the latter did not reach statistical significance. All sub-
jects completed the 14-week intervention and the 5 data
collection points except for 2 subjects in the control
group who were unavailable for data collection point #3
due to travel.
Subjects in the Active group achieved both statistically
significant (p < 0.05) and clinically significant (DGI change
of at least 4 points [13]) improvements in gait by the 6-
week test point and these improvements continued
through the 14-week test point (Figure 3 and Table 3). Sub-
jects in the control group did not achieve a statistically-
significant improvement in gait at any test points, although
the apparent improvement at Week 10 would be consid-
ered clinically significant.
When the pairwise differences in DGI change from
baseline (Table 3) are compared for the two groups, the
active group shows a statistically-significant greater im-
provement than the control group at 10 weeks (p = 0.027)
and 14 weeks (p < 0.001), using the independent t-test.
(The Corresponding p values for the Wilcoxon test were
0.034 and 0.002).
The raw DGI data from this study are shown in Table 4a.
It can be seen that every Active group subject (100%), and
all but one in the Control group (90%) exhibited some im-
provement in their score between baseline and the end of
the study at 14-weeks. The major difference is the magni-
tude of both the individual and mean group change be-
tween the two treatment groups. On average, the Active
group improved by 7.95 points, while the Control group
exhibited a mean change of 3.45 points.
All subjects reported an increase in salivation at the
outset of the study due to the presence of the device in
the mouth. With instruction, each was able to developFigure 3 Plot of Change in DGI score versus time within the
study period. The horizontal axis represents data acquisition time:
0 weeks is study entry (baseline), 2 weeks is end of lab training, and
6, 10, and 14 weeks are end of each 4-week home training period.
The vertical axis represents the change in DGI relative to the
baseline DGI value. Error bars are ± 1 SE; * indicates p < 0.05, **
indicates p < .005.
Table 4 Raw DGI scores









Active 1 8 8.5 9.5 9.5 12
Active 2 10 13.5 13.5 16 16.5
Active 3 10 16 18 17 20
Active 4 10.5 14.5 15.5 17.5 17
Active 5 6 10 12.5 13 14
Active 6 5.5 10 12 13 11.5
Active 7 7.5 10 14 17 17.5
Active 8 13 21 20 21 19.5
Active 9 13 17 16.5 22.5 21.5
Active 10 5.5 12.5 19 19.5 19
Control 1 11.5 16.5 18.5 19.5 15.5
Control 2 17 22 21.5 19
Control 3 13.5 16 18 16.5
Control 4 14 15 18 18 21
Control 5 14.5 14 16 17 16.5
Control 6 4 8.5 8 6.5 4
Control 7 15 20.5 20.5 21 18
Control 8 6 9 8.5 8 9.5
Control 9 12 15 18.5 18.5 18.5
Control 10 12 13 17 19.5 15.5
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maintaining the device in their mouth. Five subjects also
reported mild headaches and temporo-mandibular joint
pain during the first few days of participation. These
symptoms were mitigated by the end of the 2-week in-
lab training period by instructing them to not bite the
array, relax their jaw, press the array firmly with the
tongue, and breathe uniformly. Two RRMS subjects in
the Active group experienced relapses requiring suspen-
sion of their participation, one for a period of 5 weeks,
the others for 3 months. When they were able to resume
training at the same level they had achieved prior to the
relapse they were reintegrated into the study without
adverse effect. Three subjects (2 Control, one Active
group) experienced minor illnesses that required suspen-
sion of training for approximately 2 weeks each. Each
was able to resume training without complication, and
their testing schedules adjusted accordingly. Finally, sev-
eral subject experienced fatigue after completion of the
morning training session. They were encouraged to
practice relaxation exercises to help them prepare for
performing the afternoon sessions. This proved to be a
useful skill for them to develop in managing their energy
levels so that they could consistently complete their daily
participation in the study.Discussion
This study investigated whether individuals with mul-
tiple sclerosis could improve their gait using CN-NINM
intervention, a training program that incorporates exer-
cises combined with noninvasive electrical stimulation of
the tongue. The results show that subjects in the active
group had greater improvements in their gait relative to
the control group, and the improvements were clinically
and statistically significant.
The sample size of this study was small (10 subjects
per group), which may limit the external validity of the
results. The sample size estimation for this study was
based on the robust results of our earlier non-controlled
proof of concept studies.
In considering sources of the induced improvement, our
previous studies have demonstrated through fMRI that
neuromodulation training using electrical stimulation of
the tongue, combined with movement exercises in balance-
impaired individuals, induces activity of the cerebellum and
brainstem nuclei, structures of the brain that process
balance and movement [44,45,52]. Additionally, Mori,
et al. showed that using transcranial magnetic stimulation
combined with exercise therapy resulted in a reduction
in spasticity and fatigue [35]. These findings, combined
with known afferent neural pathways from the tongue, sug-
gest that tongue stimulation preferentially predisposes
certain cerebellum and brainstem nuclei to beneficial neu-
roplastic effects resulting from movement exercises de-
pendent on these nuclei, with the end result of improved
movement control.
We hypothesize that CN-NINM induces neuroplasti-
city by noninvasive stimulation of two major cranial
nerves: trigeminal, CN-V, and facial, CN-VII. This stimu-
lation excites a flow of action potentials (AP’s) to the
brainstem (pons varolli and medulla) and cerebellum via
the lingual branch of the cranial nerve (CN-Vc), and
chorda tympani branch of CN-VII. This effect of the
stimulation extends to the corresponding nuclei of the
brainstem – at least in the sensory and spinal nuclei of
trigeminal nuclear complex and the caudal part of the
nucleus tractus solitarius [44,45,52]. We postulate that
the intensive activation of these structures initiates a se-
quential cascade of changes in neighboring and/or con-
nected nuclei by direct collateral connections, brainstem
interneuron circuitry and/or passive transmission of bio-
chemical compounds in the intercellular space. There
is evidence from related research that has observed
changes in both neurotransmitter and other neuroactive
compounds in response to chronic stimulation. Each AP
in the trigeminal nuclei and brainstem releases up to 23
biologically active compounds including neurotransmit-
ters that affect synaptic transmission, and the brainstem
has the highest glia-to-neuron density anywhere in the
CNS (50:1) [61]. The full function of the glial network is
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a vital role in the regulation of neural behavior through
management of the chemical environment at the synap-
tic gap. Consequently, we believe the stimulation directly
activates not only the neuronal network by electrical
impulses (AP’s) but also the glial network by neuro-
chemical impact. The net effect of this upregulation of
neuroactive compounds is to potentiate the networks in-
volved within the CNS and set the stage for sustained
focal and global changes in brain behavior [62-68].
Improvement is also common in patients receiving a
new intervention with a therapist [7,69]. A better indica-
tion of efficacy is if the patient improves when inde-
pendently training at home. Here we see that both
groups continued to improve during the at-home phase
of the study. In a related study, Di Fabio, et al., found
that patients with progressive MS who continued with
an extended home outpatient rehabilitation over the
course of 1 year experienced a lower rate of decline in
physical function when compared with subjects who did
not exercise [70,71]. Our study did not compare subjects
who had performed the extended exercise protocol with
any who had exercised and stopped. Consequently, to
investigate this phenomenon, the natural progression of
this study would be to repeat it using a longer interven-
tion period.
In our study, though all subjects appeared to demon-
strate improvements initially, only the active group con-
tinued to improve over the length of the study. It is
likely that the early improvement in both groups was
due to the intense involvement of the subjects with the
trainers for the first 2 weeks of the study. It can been
seen in Table 3 that improvements in performance for
the active group continued to accumulate as subjects
trained at home after the initial 2-week training phase.
Subjects who trained using exercise only without stimu-
lation (control group) continued to improve for the first
month at home and then exhibited a plateau or even a
decrease in performance. This provides preliminary evi-
dence that the intervention is effective when performed
independently at home.
We observed a significant difference between groups
for number of years with MS, with those in the active
group having had MS for a longer period of time. Be-
cause the progression of the disease varies from person
to person, however, we did not feel that chronicity (years
with MS) was as important as symptom presentation.
We based our inclusion criteria on symptom presenta-
tion, specifically gait dysfunction, and EDSS score. We
also observed that the mean initial (baseline) DGI score
was lower in the active group (although this did not ap-
proach statistical significance), raising the concern that
this may bias the results. Because of this apparent differ-
ence, we chose to analyze data using a simple DGIdifference from baseline, rather than a % change as sug-
gested by other groups which would have unduly favored
the active group [60]. Similar analysis of % DGI change
yielded identical conclusions.
We did not investigate whether the subtype of MS had
an effect on the reported outcomes. It is acknowledged
that because subject assignment was purely random
there is some possibility that the disease subtype could
affect sensitivity to the intervention and therefore the re-
sults. We note, however, that these sub-classifications re-
late primarily to the progression of the disease and not
to their particular state during participation in the study.
Furthermore, we excluded all candidates that had any
changes in symptoms or medication in the 3 months
prior to participation to ensure that their presentation
was as stable as possible. Nonetheless, it would be bene-
ficial to repeat this study using only MS patients of one
particular type, such as PPMS or SPMS to determine if
the rate or magnitude of change in performance differs
as a function of the disease sub-classification.
The remaining question that may be posed is whether
CN-NINM training could be practically deployed in a re-
habilitation setting. The in-lab training for this study was
admittedly time intensive (approximately 2 to 3 hours
per day, per subject), involving far more time for therapy
than a typical clinical setting would allow. This was an
intentional departure from most therapeutic models for
rehabilitation, derived from our prior experience with
treating vestibular disorders [43,46]. Given the rigors of
the intervention, and the nature of this neurodegenerative
disease, this intensive in-lab phase was designed to ensure
that subjects understood and could reliably perform the
training program before using the device at home. The re-
sults suggest that this new paradigm for home-health re-
habilitation, particularly for disorders previously deemed
untreatable, is efficacious. Additional studies are necessary
to determine if an abbreviated intervention would be as
effective as the model presented here.
Conclusions
The results of this pilot RCT demonstrate that non-
invasive electrotactile stimulation, when combined with
targeted physical therapy exercises, can significantly re-
duce clinical symptoms of gait dysfunction in multiple
sclerosis. This complements a growing body of evidence
demonstrating that neuromodulation combining elec-
trical stimulation with exercise therapy has the potential
to have a positive effect on motor control for people
with neurological conditions. The results also demon-
strate that the CN-NINM intervention shows promise
for development as a clinical tool for improvement in
gait in people with MS. Additionally, because the tongue
stimulation device is portable it allows people to train at
home, affording an efficacious therapeutic model not
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people with other types of neurological conditions would
benefit from this type of intervention to improve motor
control. We suggest that further studies are warranted
to investigate the breadth of applicability that this form
of therapeutic intervention may have for meaningful
neurorehabilitation.
Endnotes
aWhile not formally approved, half-point scores (0.5)
of the DGI are commonly used. The author of the DGI
(Shumway-Cook) has acknowledged the limitations of
the scale as originally constructed, and conceded that, if
employed consistently by the clinician, the use of 0.5
interval is an acceptable interpolation of the defined
condition on conventional scale.
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